11:01 AM EDT, 03/27/2024 (MT Newswires) -- Hamilton Thorne Ltd. ( HTLZF ) , a provider of precision instruments, laboratory equipment, consumables, software, and services to the Assisted Reproductive Technologies, research, and cell biology markets, was at last look on Wednesday up 1.5% after reporting fourth-quarter earnings of $540,237, or $0.00 per diluted share, down from $980,391, or $0.00 per diluted share, a year earlier.

Sales for the quarter ended Dec. 31, 2023, were $18.4 million, up from $16.4 million a year earlier. Adjusted EBITDA for Q4 was $3.7 million, up from $3 million a year earlier.

The company is expecting first-quarter revenue of $19 million to $19.4 million, with organic growth for the quarter of about 8%.

For the full 12 months of 2024, the company expects to deliver revenue of $78 to $82 million, reflecting 10% to 15% organic growth for the full year.

"In 2023, we made significant investments in our operations to facilitate long-term growth. Management is committed to EBITDA margin expansion and we anticipate tighter operating expense control in 2024, while continue to leverage our larger scale. We anticipate Q1 of 2024 to be our lowest EBITDA margin quarter in 2024 at approximately 18%, but in the range of 19.5% to 20.5% for the full year. Cash flow is expected to improve as the investment in expanding capacity has been completed and inventory will decrease in the following months," Francesco Fragasso, the company's chief financial officer, said.

Price: 1.32, Change: +0.02, Percent Change: +1.54